120 related articles for article (PubMed ID: 20384524)
1. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
2. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Gordon EM; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Bruckner HW; Hall FL
Int J Oncol; 2006 Nov; 29(5):1053-64. PubMed ID: 17016635
[TBL] [Abstract][Full Text] [Related]
3. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
[TBL] [Abstract][Full Text] [Related]
4. The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
Gordon EM; Hall FL
Int J Oncol; 2009 Aug; 35(2):229-38. PubMed ID: 19578735
[TBL] [Abstract][Full Text] [Related]
5. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
6. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
8. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Chawla SP; Chua VS; Fernandez L; Quon D; Blackwelder WC; Gordon EM; Hall FL
Mol Ther; 2010 Feb; 18(2):435-41. PubMed ID: 19826403
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology blooms, at last (Review).
Gordon EM; Hall FL
Oncol Rep; 2005 Jun; 13(6):1003-7. PubMed ID: 15870914
[TBL] [Abstract][Full Text] [Related]
10. Cancer gene therapy steadily advances.
Brower V
J Natl Cancer Inst; 2008 Sep; 100(18):1276-8. PubMed ID: 18780858
[No Abstract] [Full Text] [Related]
11. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
12. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.
Chawla SP; Bruckner H; Morse MA; Assudani N; Hall FL; Gordon EM
Mol Ther Oncolytics; 2019 Mar; 12():56-67. PubMed ID: 30705966
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM; Liu PX; Chen ZH; Liu L; Whitley MD; Gee C; Groshen S; Hinton DR; Beart RW; Hall FL
Cancer Res; 2000 Jul; 60(13):3343-7. PubMed ID: 10910035
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: Sch-58500, Canji.
Barnard DL
Curr Opin Mol Ther; 2000 Oct; 2(5):586-92. PubMed ID: 11249761
[TBL] [Abstract][Full Text] [Related]
15. Development and application of adenoviral vectors for gene therapy of cancer.
Zhang WW
Cancer Gene Ther; 1999; 6(2):113-38. PubMed ID: 10195879
[TBL] [Abstract][Full Text] [Related]
16. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
Gordon EM; Hall FL
Int J Oncol; 2010 Jun; 36(6):1341-53. PubMed ID: 20428757
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
Bauerschmitz GJ; Barker SD; Hemminki A
Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
[TBL] [Abstract][Full Text] [Related]
18. Viral vector-mediated gene transfer for CNS disease.
Snyder BR; Boulis NM; Federici T
Expert Opin Biol Ther; 2010 Mar; 10(3):381-94. PubMed ID: 20132059
[TBL] [Abstract][Full Text] [Related]
19. Genetically marking human cells--results of the first clinical gene transfer studies.
Cai Q; Rubin JT; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
